• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The EMGT: Reducing intraocular pressure slows progression of glaucoma [Classics Series]

byEvan ChenandAndrew Cheung, MD MBA
December 31, 2015
in General Medicine Classics, Surgery Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Treatment using laser trabeculoplasty and topical betaxolol hydrochloride to reduce intraocular pressure (IOP) is associated with delayed progression of glaucoma

2. Treatment to decrease IOP was associated with an increase in nuclear lens opacity grading indicative of cataract formation

Original Date of Publication: October 2002

Study Rundown: Previous epidemiological studies had suggested that few patients with elevated IOP actually developed glaucoma when left untreated. This challenged two assumptions at the time: firstly, the belief that glaucoma was caused by elevated IOP, and secondly, the thought that reducing IOP was a means of treating glaucoma. The Early Manifest Glaucoma Trial (EMGT), which commenced in 1992, was the first adequately powered, randomized trial that assessed the effectiveness of reducing IOP in the treatment of patients with previously untreated glaucoma. Its results showed that reduction of IOP through laser trabeculoplasty and topical betaxolol significantly delayed the onset of disease progression by a median of 18 months compared to the untreated control group. The benefits of treatment remained when participants were stratified according to IOP level, degree of visual damage, age, and presence of exfoliative glaucoma. However, IOP reduction was also associated with a significant increase in cataract formation based on nuclear opacity measurements.

Limitations of the trial include the study’s homogeneous patient population, consisting predominantly of white patients. Study participants were also required to have an IOP ≤30 mm Hg, which precluded the study from assessing the effect of IOP reduction in patients with higher initial IOP levels. Also, for ethical reasons, participants in the control group were monitored only until the onset of disease progression, at which point participants were then given appropriate treatment at the time. This design prevented the study from observing the natural history of glaucoma for an extended period of time. In summary, while the results of the EMGT do not conclusively show that elevated IOP causes glaucoma, it does confirm that elevated IOP is an important component of glaucoma’s pathophysiology, and that reducing IOP can help slow the progression of glaucoma in patients of various age, IOP level, and other characteristics. This finding supports efforts to improve early-detection of elevated IOP in patients.

Click here to read the study in JAMA Ophthalmology

In-Depth [randomized controlled trial]: The EMGT was a randomized trial that enrolled 255 patients from two Swedish cities. Eligible patients had to have had a diagnosis of newly detected, previously untreated open-angle glaucoma, reproducible visual deficits, and be between 50 and 80 years of age. Exclusion criteria included having severe visual field defects, a mean IOP >30 mm Hg, and significant cataractous lens changes. A total of 129 participants were randomized to receive treatment to reduce IOP through laser trabeculoplasty and topical betaxolol, while 126 participants were randomized to receive no treatment. All patients were monitored until the moment of disease progression, whereupon appropriate treatment was administered for all patients. Progression of glaucoma was assessed via measurements of visual field defects and optic disc cupping. All graders for these measurements were blinded.

RELATED REPORTS

Heavy smoking is associated with visual field loss in glaucoma

#VisualAbstract: Primary trabeculectomy vs. medical management for advanced glaucoma have similar outcomes

Primary trabeculectomy associated with similar outcomes as medical management for advanced glaucoma

Median follow-up was 6 years (range 51-102 months). The study demonstrated that treatment to reduce IOP was associated with a significantly lower frequency of glaucoma progression when compared with no treatment (45% vs. 62%, p = 0.007). This benefit of reducing IOP remained when patients were stratified according IOP level, degree of visual damage, age, and presence of exfoliation. The median time to progression for the treatment group was 18 months longer than for the control group. The study also found that treatment to reduce IOP levels was associated with a significant increase in nuclear opacities, when compared with no treatment (p = 0.002).

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: emgtglaucoma
Previous Post

Treatment risk may outweigh benefit for asymptomatic chorioamnionitis-exposed infants

Next Post

Planned out-of-hospital birth associated with higher mortality

RelatedReports

Smoking during pregnancy associated with aerobic fitness of children
Ophthalmology

Heavy smoking is associated with visual field loss in glaucoma

June 28, 2022
#VisualAbstract: Primary trabeculectomy vs. medical management for advanced glaucoma have similar outcomes
StudyGraphics

#VisualAbstract: Primary trabeculectomy vs. medical management for advanced glaucoma have similar outcomes

May 26, 2021
Quick Take: Association of Visual Impairment With Economic Development Among Chinese Schoolchildren
Emergency

Primary trabeculectomy associated with similar outcomes as medical management for advanced glaucoma

May 18, 2021
Adalimumab aids in control of noninfectious uveitis
Ophthalmology

Schlemm canal microstent implantation associated with long-term reduction in intraocular pressure and need for additional surgeries

November 23, 2020
Next Post
Medicaid home-visitation program linked to reduced infant mortality

Planned out-of-hospital birth associated with higher mortality

Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

Periconceptional folic acid for prevention of neural tube defects [Classics Series]

History of maternal anorexia linked to small infant size

History of maternal anorexia linked to small infant size

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Ciprofol comparable to propofol for general anesthesia induction for gynecological surgery
  • Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy
  • Type of compensation model influences gender pay gap in primary care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.